These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31219366)

  • 1. Assessment of cognitive functions and psychiatric symptoms in hepatitis C patients receiving pegylated interferon alpha and ribavirin: A prospective cohort study.
    Hassaan SH; Darwish AM; Khalifa H; Ramadan HKA; Hassany SM; Ahmed GK; Moustafa EF
    Int J Psychiatry Med; 2019 Nov; 54(6):424-440. PubMed ID: 31219366
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-α-2b and ribavirin.
    Phillips FH; Prebis M; Grumbeck C; Hale T; Cubillas R; Brown GR
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1435-42. PubMed ID: 20802340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
    Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
    Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 5. Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
    de Mattos AZ; de Almeida PR; Tovo CV; de Mattos AA
    Hepatology; 2010 Nov; 52(5):1867. PubMed ID: 20726033
    [No Abstract]   [Full Text] [Related]  

  • 6. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 8. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.
    Pennisi M; Bertino G; Gagliano C; Malaguarnera M; Bella R; Borzì AM; Madeddu R; Drago F; Malaguarnera G
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28820468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
    Diez-Quevedo C; Masnou H; Planas R; Castellví P; Giménez D; Morillas RM; Martín-Santos R; Navinés R; Solà R; Giner P; Ardèvol M; Costa J; Diago M; Pretel J
    J Clin Psychiatry; 2011 Apr; 72(4):522-8. PubMed ID: 21034680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients.
    Ebner N; Wanner C; Winklbaur B; Matzenauer C; Jachmann CA; Thau K; Fischer G
    Addict Biol; 2009 Apr; 14(2):227-37. PubMed ID: 19291011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
    Lang JP; Melin P; Ouzan D; Rotily M; Fontanges T; Marcellin P; Chousterman M; Cacoub P;
    Antivir Ther; 2010; 15(4):599-606. PubMed ID: 20587853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 18. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
    Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin.
    Mukherjee S; Ariyarantha K
    Transplantation; 2007 Nov; 84(10):1374-5. PubMed ID: 18049127
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of acute hepatitis C with PEG-interferon and ribavirin].
    Nicolas I; Pons JA
    Gastroenterol Hepatol; 2003 Apr; 26(4):275-6. PubMed ID: 12681125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.